Clinical Research Directory
Browse clinical research sites, groups, and studies.
Extension Study of MYL-1701P-3001 for Safety and Efficacy
Sponsor: Mylan Pharmaceuticals Inc
Summary
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
Official title: A Multi Center, Extension Study to Evaluate the Safety and Efficacy of MYL-1701P in Subjects With Diabetic Macular Edema Completed MYL-1701P-3001 Study.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2020-11-23
Completion Date
2022-04-20
Last Updated
2026-08-03
Healthy Volunteers
No
Conditions
Interventions
MYL-1701P, a proposed biosimilar to Eylea
MYL-1701P- 3 doses each of 2 mg at 8 weeks interval
Locations (15)
Mylan Investigative site
Hyderabad, Andhra Pradesh, India
Mylan Investigative Site
Visakhapatnam, Andhra Pradesh, India
Mylan Investigative Site
Ahmedabad, Gujarat, India
Mylan Investigative site
Ahmedabad, Gujarat, India
Mylan Investigative site
Bangalore, Karnataka, India
Mylan Investigative Site
Bangalore, Karnataka, India
Mylan Investigative Site
Bengaluru, Karnataka, India
Mylan Investigative Site
Mumbai, Maharashtra, India
Mylan Investigative site
New Delhi, New Delhi, India
Mylan Investigative site
Bhubaneswar, Odisha, India
Mylan Investigative Site
Chandigarh, Punjab, India
Mylan Investigative site
Jaipur, Rajasthan, India
Mylan Investigative site
Madurai, Tamil Nadu, India
Mylan Investigative site
Tirunelveli, Tamil Nadu, India
Mylan Investigative Site
Noida, Uttar Pradesh, India